If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Camillo Porta is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 16 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors

Santoni, M., Heng, D. Y., Bracarda, S., Procopio, G., Milella, M., Porta, C., Matrana, M. R., Cartenì, G., Crabb, S. J., De Giorgi, U., Basso, U., Masini, C., Calabrò, F., Vitale, M. G., Santini, D., Massari, F., Galli, L., Fornarini, G., Ricotta, R., Buti, S. & 29 others, Zucali, P., Caffo, O., Morelli, F., Carrozza, F., Martignetti, A., Gelibter, A., Iacovelli, R., Mosca, A., Atzori, F., Vau, N., Incorvaia, L., Ortega, C., Scarpelli, M., Lopez-Beltran, A., Cheng, L., Paolucci, V., Graham, J., Pierce, E., Scagliarini, S., Sepe, P., Verzoni, E., Merler, S., Rizzo, M., Sorgentoni, G., Conti, A., Piva, F., Cimadamore, A., Montironi, R. & Battelli, N., Jan 2020, In : Cancers. 12, 1, 84.

Research output: Contribution to journalArticle

Open Access
  • Acute Kidney Injury in Oncology and Tumor Lysis Syndrome

    Cosmai, L., Porta, C., Ronco, C. & Gallieni, M., Jan 1 2019, Critical Care Nephrology: Third Edition. Elsevier Inc., p. 234-250.e1

    Research output: Chapter in Book/Report/Conference proceedingChapter

  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Rini, B. I., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Lee, J. L., Hawkins, R., Ravaud, A., Alekseev, B., Staehler, M., Uemura, M., De Giorgi, U., Mellado, B., Porta, C., Melichar, B., Gurney, H. & 12 others, Bedke, J., Choueiri, T. K., Parnis, F., Khaznadar, T., Thobhani, A., Li, S., Piault-Louis, E., Frantz, G., Huseni, M., Schiff, C., Green, M. C. & Motzer, R. J., Jun 15 2019, In : The Lancet. 393, 10189, p. 2404-2415 12 p.

    Research output: Contribution to journalArticle

  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Rini, B. I., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Lee, J. L., Hawkins, R., Ravaud, A., Alekseev, B., Staehler, M., Uemura, M., De Giorgi, U., Mellado, B., Porta, C., Melichar, B., Gurney, H. & 13 others, Bedke, J., Choueiri, T. K., Parnis, F., Khaznadar, T., Thobhani, A., Li, S., Piault-Louis, E., Frantz, G., Huseni, M., Schiff, C., Green, M. C., Motzer, R. J. & Group, IM. S., Jun 15 2019, In : Lancet (London, England). 393, 10189, p. 2404-2415 12 p.

    Research output: Contribution to journalArticle